Skip to main content
SpringerLink
Log in

Therapeutical Approaches

  • Chapter
Life with Epidermolysis Bullosa (EB)

Abstract

All forms of epidermolysis bullosa (EB) are characterized by skin fragility and cutaneous injury. Hence, wound healing is the dominant issue of disease management in all types of EB. Due to ongoing blistering, persistent inflammatory activity, polymicrobial colonization with frequent infections, poor nutritional status, and oxygen supply, EB lesions often become chronic, non-healing wounds. This causes considerable pain, daily extended wound dressings with costs to the patient, family, and healthcare providers [36].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abahussein AA, al-Zayir AA, Mostafa WZ, Okoro AN (1992) Recessive dystrophic epidermolysis bullosa treated with phenytoin. Int J Dermatol 31:730–732

    PubMed  CAS  Google Scholar 

  2. Abahussein AA, al-Zayir AA, Mostafa WZ, Okoro AN (1993) Epidermolysis bullosa in the eastern province of Saudi Arabia. Int J Dermatol 32:579–581

    PubMed  CAS  Google Scholar 

  3. Altomare GF, Polenghi M, Pigatto PD, Nazzaro V, Piattoni F (1990) Dystrophic epidermolysis bullosa inversa: a case report. Dermatologica 181:145–148

    PubMed  CAS  Google Scholar 

  4. Arbiser JL, Fine JD, Murrell D, et al (1998) Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 4:191–195

    PubMed  CAS  Google Scholar 

  5. Armoni M, Schlesinger M, Vardy PA, Metzker A (1985) Phenytoin and junctional epidermolysis bullosa. Arch Dermatol 121:168–169

    PubMed  CAS  Google Scholar 

  6. Bauer EA, Gedde-Dahl T Jr, Eisen AZ (1977) The role of human skin collagenase in epidermolysis bullosa. J Invest Dermatol 68:119–124

    PubMed  CAS  Google Scholar 

  7. Beyne B (1982) Favorable effect of the sulfamethoxazole-trimethoprim combination on the evolution of congenital bullous epidermolysis of the dystrophic form. Nouv Presse Med 11:3730

    PubMed  CAS  Google Scholar 

  8. Bugge TH, et al (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87:709–719

    PubMed  CAS  Google Scholar 

  9. Caldwell-Brown D, Stern RS, Lin AN, Carter DM (1992) Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. N Engl J Med 327:163–167

    PubMed  CAS  Google Scholar 

  10. Clark RA, et al (1982) Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol 79:264–269

    PubMed  CAS  Google Scholar 

  11. Clark RA (1990) Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J Invest Dermatol 94:128S–134S

    PubMed  CAS  Google Scholar 

  12. Clark RA, Nielsen LD, Welch MP, McPherson JM (1995) Collagen matrices attenuate the collagen-synthetic response of cultured fibroblasts to TGF-beta. J Cell Sci 108 (Pt 3):1251–1261

    PubMed  CAS  Google Scholar 

  13. Clark RA, Ashcroft GS, Spencer MJ, Larjava H, Ferguson MW (1996) Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins. Br J Dermatol 135:46–51

    PubMed  CAS  Google Scholar 

  14. Cooper TW, Bauer EA (1984) Therapeutic efficacy of phenytoin in recessive dystrophic epidermolysis: a comparison of short-and long-term treatment. Arch Dermatol 120:490–495

    PubMed  CAS  Google Scholar 

  15. Cunnane SC, Kent ET, McAdoo KR, Caldwell D, Lin AN, Carter DM (1987) Abnormalities of plasma and erythrocyte essential fatty acid composition in epidermolysis bullosa: influence of treatment with diphenylhydantoin. J Invest Dermatol 89:395–399

    PubMed  CAS  Google Scholar 

  16. Desmouliere A, Redard M, Darby I, Gabbiani G (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 146:55–66

    Google Scholar 

  17. Eisenberg M, Stevens LH, Schofield PJ (1978) Epidermolysis bullosa: new therapeutic approaches. Australas J Dermatol 19:1–8

    PubMed  CAS  Google Scholar 

  18. Falabella AF, Valencia IC, Eaglstein WH, Schachner LA (2000) Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 136:1225–1230

    PubMed  CAS  Google Scholar 

  19. Featherstone C (2007) Epidermolysis bullosa: from fundamental molecular biology to clinical therapies. J Invest Dermatol 127:256–259

    PubMed  CAS  Google Scholar 

  20. Fine J-D (2007) Epidermolysis bullosa: a genetic disease of altered cell adhesion and wound healing, and the possible clinical utility of topically applied thymosin β4. Ann NY Acad Sci 1112:396–406

    PubMed  CAS  Google Scholar 

  21. Fine JD, Johnson L (1988) Efficacy of systemic phenytoin in the treatment of junctional epidermolysis bullosa. Arch Dermatol 124:1402–1406

    PubMed  CAS  Google Scholar 

  22. Fine JD, Eady RAJ (1999) Tetracycline and epidermolysis bullosa simplex — a new indication for one of the oldest and most widely used drugs in dermatology? Arch Dermatol 135:981–982

    PubMed  CAS  Google Scholar 

  23. Gabbiani G, Chaponnier C, Huttner I (1978) Cytoplasmic filaments and gap junctions in epithelial cells and myofibroblasts during wound healing. J Cell Biol 76:561–568

    PubMed  CAS  Google Scholar 

  24. Genever PG, Cunliffe WJ, Wood EJ (1995) Influence of the extracellular matrix on fibroblast responsiveness to phenytoin using in vitro wound healing models. Br J Dermatol 133:231–235

    PubMed  CAS  Google Scholar 

  25. Goldfinger LE, Stack MS, Jones JC (1998) Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol 141:255–265

    PubMed  CAS  Google Scholar 

  26. Goliger JA, Paul DL (1995) Wounding alters epidermal connexin expression and gap junction-mediated intercellular communication. Mol Biol Cell 6:1491–1501

    PubMed  CAS  Google Scholar 

  27. Gonzales M, et al (1999) A cell signal pathway involving laminin-5, alpha3betal integrin, and mitogen-activated protein kinase can regulate epithelial cell proliferation. Mol Biol Cell 10:259–270

    PubMed  CAS  Google Scholar 

  28. Guill MF, Wray BB, Rogers RB, Others (1983) Junctional epidermolysis bullosa — treatment with phenytoin. Am J Dis Child 137:992–994

    PubMed  CAS  Google Scholar 

  29. Hartwig B, et al (2007) Laminin-5-deficient human keratinocytes: defective adhesion results in a saltatory and inefficient mode of migration. Exp Cell Res 313:1575–1587

    PubMed  CAS  Google Scholar 

  30. Hon J (2005) Using honey to heal a chronic wound in a patient with epidermolysis bullosa. Br J Nurs 14:S4–S12

    Google Scholar 

  31. Kero M (1984) Epidermolysis bullosa in Finland: clinical features, morphology and relation to collagen metabolism. Acta Derm Venereol (Stockholm) [Suppl] 110:1–51

    CAS  Google Scholar 

  32. Lanschuetzer CM, et al (2003) Pathogenic mechanisms in epidermolysis bullosa naevi. Acta Derm Venereol 83:322–337

    Google Scholar 

  33. Larregue M, et al (1990) Epidermolysis bullosa herpetiformis of Dowling-Meara. Ann Dermatol Venereol 117:802–804

    PubMed  CAS  Google Scholar 

  34. Masgrau-Peya E, Lacour M, Salomon D (1995) Topical phenytoin accelerates healing in epidermolysis bullosa simplex. Dermatology 190:254

    PubMed  CAS  Google Scholar 

  35. McClain SA, et al (1996) Mesenchymal cell activation is the rate-limiting step of granulation tissue induction. Am J Pathol 149:1257–1270

    PubMed  CAS  Google Scholar 

  36. Mellerio JE, et al (2007) Medical management of epidermolysis bullosa: Proceedings of the 2nd international symposium on epidermolysis bullosa, Santiago, Chile, 2005. Int J Dermatol 46:795–800

    PubMed  Google Scholar 

  37. Molan PC (2006) The evidence supporting the use of honey as a wound dressing. Int J Low Extrem Wounds 5:40–54

    PubMed  CAS  Google Scholar 

  38. Moy LS, Tan EM, Holness R, Uitto J (1985) Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblast cultures. Arch Dermatol 121:79–83

    PubMed  CAS  Google Scholar 

  39. Nawaz A, Matta H, Jacobsz A, Al-Salem A (2000) Congenital pyloric atresia and junctional epidermolysis bullosa: a report of two cases. Pediatr Surg Int 16:206–208

    PubMed  CAS  Google Scholar 

  40. Nguyen BP, Ryan MC, Gil SG, Carter WG (2000) Deposition of laminin 5 in epidermal wounds regulates integrin signaling and adhesion. Curr Opin Cell Biol 12:554–562

    PubMed  CAS  Google Scholar 

  41. Nguyen BP, Ren XD, Schwartz MA, Carter WG (2001) Ligation of integrin alpha 3 beta 1 by laminin 5 at the wound edge activates Rho-dependent adhesion of leading keratinocytes on collagen. J Biol Chem 276:43860–43870

    PubMed  CAS  Google Scholar 

  42. Oakley CA, Wilson N, Ross JA, Barnetson RSC (1984) Junctional epidermolysis bullosa in two siblings: clinical observations, collagen studies and electron microscopy. Br J Dermatol 111:533–543

    PubMed  CAS  Google Scholar 

  43. Ozanic Bulic S, Fassihi H, Mellerio J, McGrath JA, Atherton DJ (2005) Thalidomide in the management of epidermolysis bullosa pruriginosa. Br J Dermatol 152:1332–1334

    PubMed  CAS  Google Scholar 

  44. Pilcher BK, et al (1997) The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137:1445–1457

    PubMed  CAS  Google Scholar 

  45. Retief CR, Malkinson FD, Pearson RW (1999) Two familial cases of epidermolysis bullosa simplex successfully treated with tetracycline. Arch Dermatol 135:997–998

    PubMed  CAS  Google Scholar 

  46. Scheinfeld N (2003) Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatol Online J 9:6

    PubMed  Google Scholar 

  47. Schneider H, Muhle C, Pacho F (2007) Biological function of laminin-5 and pathogenic impact of its deficiency. Eur J Cell Biol 86:701–717

    PubMed  CAS  Google Scholar 

  48. Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D (2003) Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 49:23–51

    PubMed  Google Scholar 

  49. Sibbald RG, et al (2005) Using a dermal skin substitute in the treatment of chronic wounds secondary to recessive dystrophic epidermolysis bullosa: a case series. Ostomy Wound Manage 51:22–46

    PubMed  Google Scholar 

  50. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738–746

    PubMed  CAS  Google Scholar 

  51. Talas G, Adams TS, Eastwood M, Rubio G, Brown RA (1997) Phenytoin reduces the contraction of recessive dystrophic epidermolysis bullosa fibroblast populated collagen gels. Int J Biochem Cell Biol 29:261–270

    PubMed  CAS  Google Scholar 

  52. Tyring SK, Chopra V, Johnson L, Fine JD (1989) Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 125:797–800

    PubMed  CAS  Google Scholar 

  53. Weiner M, Stein A, Cash S, DeLeoz J, Fine J-D (2004) Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial. Br J Dermatol 150:613–614

    PubMed  CAS  Google Scholar 

  54. Welch MP, Odland GF, Clark RA (1990) Temporal relationships of F-actin bundle formation, collagen and fibronectin matrix assembly, and fibronectin receptor expression to wound contraction. J Cell Biol 110:133–145

    PubMed  CAS  Google Scholar 

  55. Werner S, et al (1994) The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 266:819–822

    PubMed  CAS  Google Scholar 

  56. Wessagowit V, Mallipeddi R, McGrath JA, South AP (2004) Altered expression of L-arginine metabolism pathway genes in chronic wounds in recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 29:664–668

    PubMed  CAS  Google Scholar 

  57. Woodley DT, Keen DR, Atha T, et al (2004) Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10:318–326

    PubMed  CAS  Google Scholar 

  58. Woodley DT, Keen DR, Atha T, et al (2004) Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10:693–695

    PubMed  CAS  Google Scholar 

  59. Woodley DT, Remington J, Huang Y, et al (2007) Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15:628–635

    PubMed  CAS  Google Scholar 

  60. Xu J, Clark RA (1996) Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol 132:39–249

    Google Scholar 

  61. Yen SL, Chao LH, Ho MM, Hwang KC (1990) Epidermolysis bullosa: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 31:383–387

    PubMed  CAS  Google Scholar 

References

  1. IASP Subcommittee on Taxonomy (1979) Pain terms: a list with definitions and notes on usage: recommended by the IASP Subcommittee on Taxonomy. Pain 6:249

    Google Scholar 

  2. Berde CB, Sethna NF (2002) Analgesics for the treatment of pain in children. N Engl J Med 347:1094–1103

    PubMed  CAS  Google Scholar 

  3. Beyer JE, McGrath PJ, Berde CB (1990) Discordance between self-report and behavioral pain measures in children aged 3–7 years after surgery. J Pain Symptom Manage 5:350–356

    PubMed  CAS  Google Scholar 

  4. Blass EM, Watt LB (1999) Suckling-and sucrose-induced analgesia in human new-borns. Pain 83:611–623

    PubMed  CAS  Google Scholar 

  5. Chambers CT, Reid GJ, McGrath PJ, Finley GA (1996) Development and preliminary validation of a postoperative pain measure for parents. Pain 68:307–313

    PubMed  CAS  Google Scholar 

  6. Champion DG, Goodenough B, von Baeyer CL, Thomas W (1998) Measurement of pain by self-report. In: Finley GA, McGrath PJ (eds) Progress in pain research and management. IASP Press, Seattle

    Google Scholar 

  7. Chiu YK, Prendiville JS, Bennett SM, Montgomery CJ, Oberlander TF (1999) Pain management of junctional epidermolysis bullosa in an 11-year-old boy. Pediatr Dermatol 16:465–468

    PubMed  CAS  Google Scholar 

  8. Fearon I, Kisilevsky BS, Hains SM, Muir DW, Tranmer J (1997) Swaddling after heel lance: age-specific effects on behavioral recovery in preterm infants. J Dev Behav Pediatr 18:222–232

    PubMed  CAS  Google Scholar 

  9. Fine J-D, Johnson LB, Weiner M, Suchindran C (2004) Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol 29:122–127

    PubMed  Google Scholar 

  10. Herod J, Denyer J, Goldman A, Howard R (2002) Epidermolysis bullosa in children: pathophysiology, anaesthesia and pain management. Paediatr Anaesthesia 12:388–397

    Google Scholar 

  11. Horn HM, Tidman MJ (2002) Quality of life in epidermolysis bullosa. Clin Exp Dermatol 27:707–710

    PubMed  CAS  Google Scholar 

  12. Howard RF (2003) Current status of pain management in children. JAMA 290:2464–2469

    PubMed  CAS  Google Scholar 

  13. Jay S, Elliott CH, Fitzgibbons I, Woody P, Siegel S (1995) A comparative study of cognitive behaviour therapy versus general anesthesia for painful medical procedures in children. Pain 62:3–9

    PubMed  CAS  Google Scholar 

  14. Lin YC, Golianu B (2006) Anesthesia and pain management for pediatric patients with dystrophic epidermolysis bullosa. J Clin Anaesth 18:268–271

    Google Scholar 

  15. McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC (1996) A new analogue scale for assessing children’s pain: an initial validation study. Pain 64:435–443

    PubMed  CAS  Google Scholar 

  16. McIntosh N, Van VL, Brameyer H (1994) Alleviation of the pain of heel prick in preterm infants. Arch Dis Child Fetal Neonatal Ed 70:F177–F181

    PubMed  CAS  Google Scholar 

  17. Mellerio JE, et al (2007) Medical management of epidermolysis bullosa: Proceedings of the 2nd international symposium on epidermolysis bullosa, Santiago, Chile, 2005. Int J Dermatol 46:795–800

    PubMed  Google Scholar 

  18. Simons J, Franck L, Roberson E (2001) Parent involvement in children’s pain care: views of parents and nurses. J Adv Nurs 36:591–599

    PubMed  CAS  Google Scholar 

  19. Taibjee SM, Ramani P, Brown R, Moss C (2005) Lethal cardiomyopathy in epidermolysis bullosa associated with amitryptiline. Arch Dis Child 90:871–872

    PubMed  CAS  Google Scholar 

  20. Watterson G, Howard R, Goldman A (2004) Peripheral opioids in inflammatory pain. Arch Dis Child 89:679–681

    PubMed  CAS  Google Scholar 

  21. Weiner MS (2004) Pain management in epidermolysis bullosa: an intractable problem. Ostomy Wound Manage 50:13–14

    PubMed  Google Scholar 

  22. Wong DL, Baker CM (1988) Pain in children: comparison of assessment scales. Pediatr Nurs 14:9–17

    PubMed  CAS  Google Scholar 

References

  1. Banky JP, Sheridan AT, Storer EL, Marshman G (2004) Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol 140:794–796

    PubMed  Google Scholar 

  2. Buske-Kirschbaum A, Geiben A, Hellhammer D (2001) Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom 70:6–16

    PubMed  CAS  Google Scholar 

  3. Cahkoglu E, Anadolu R (2002) Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm Venereol 82:380–382

    Google Scholar 

  4. Chuang GS, Martinez-Mir A, Yu HS, et al (2004) A novel missense mutation in the COL7A1 gene underlies epidermolysis bullosa pruriginosa. Clin Exp Dermatol 29:304–307

    PubMed  CAS  Google Scholar 

  5. Chung MK, Lee H, Mizuno A, Suzuki M, Caterina MJ (2004) TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J Biol Chem 279:21569–21575

    PubMed  CAS  Google Scholar 

  6. Das JK, Sengupta S, Gangopadhyay AK (2005) Epidermolysis bullosa pruriginosa — report of three cases. Indian J Dermatol Venereol Leprol 71:109–111

    PubMed  Google Scholar 

  7. De Paulis A, Stellate C, Cirillo R, Ciccarelli A, Oriente A, Marone G (1992) Antiinflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 99:723–728

    PubMed  Google Scholar 

  8. Dowling GB, Meara RH (1954) Epidermolysis bullosa resembling juvenile dermatitis herpetiformis. Br J Dermatol 66:139–143

    PubMed  CAS  Google Scholar 

  9. Drera B, Castiglia D, Zoppi N, et al (2006) Dystrophic epidermolysis bullosa pruriginosa in Italy: clinical and molecular characterization. Clin Genet 70:339–347

    PubMed  CAS  Google Scholar 

  10. Eberlein-Konig B, Ruzicka T, Michel G, Przybilla B (1997) Modulation of histamine release in vitro by FK-506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 289:606–608

    PubMed  CAS  Google Scholar 

  11. Fine J-D, Eady RAJ, Bauer EA, et al (2000) Revised classification system for inherited epidermolysis bullosa: report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol 42:1051–1066

    PubMed  CAS  Google Scholar 

  12. Franks ME, Macpherson GR, Figg DW (2004) Thalidomide. Lancet 363:1802–1811

    PubMed  CAS  Google Scholar 

  13. Fruhstorfer H, Hermanns M, Latzke L (1986) The effects of thermal stimulation on clinical and experimental itch. Pain 24:259–269

    PubMed  CAS  Google Scholar 

  14. Furue M, Ando I, Inoue Y, Tamaki K, Oohara K, Kukita A (1986) Pretibial epidermolysis bullosa. Successful therapy with a skin graft. Arch Dermatol 122:310–313

    PubMed  CAS  Google Scholar 

  15. Ginsburg IH, Prystowsky JH, Kornfeld DS, Wolland H (1993) Role of emotional factors in adults with atopic dermatitis. Int J Dermatol 32:656–660

    PubMed  CAS  Google Scholar 

  16. Greaves MW (2007) Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 36:788–792

    PubMed  Google Scholar 

  17. Heagerty AHM, Tidman MJ, Bor S, Eady RAJ (1985) Non-lethal junctional epidermolysis bulloa in two adult sisters. J R Soc Med 78 [Suppl]:32–33

    PubMed  Google Scholar 

  18. Inoue K, Koizumi S, Fuzuwara S, Denda S, Denda M (2002) Functional vanilloid receptors in cultured human epidermal keratinocytes. Biochem Biophys Res Commun 291:124–129

    PubMed  CAS  Google Scholar 

  19. Ishida Y, Kondo T, Takayasu T, Iwakura Y, Mukaida N (2004) The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 172:1848–1855

    PubMed  CAS  Google Scholar 

  20. Ishihara M, Endo R, Rivera MR, Mihara M (2002) Bird’s eye view observations of the subepidermal nerve network of normal guinea pig skin. Arch Dermatol Res 294:281–285

    PubMed  Google Scholar 

  21. Lee NP, Arriola ER (1999) Topical corticosteroids: back to basics. West J Med 171:351–353

    PubMed  CAS  Google Scholar 

  22. McGrath JA, Ishida-Yamamoto A, Tidman MJ, Heagerty AHM, Schofield OMV, Eady RAJ (1992) Epidermolysis bullosa simplex (Dowling-Meara). A clinicopathological review. Br J Dermatol 126:421–430

    PubMed  CAS  Google Scholar 

  23. McGrath JA, Burrows NP, Russell Jones R, Eady RAJ (1993) Epidermolysis bullosa simplex Dowling-Meara: troublesome blistering and pruritus in an adult patient. Dermatology 186:68–71

    PubMed  CAS  Google Scholar 

  24. McGrath JA, Schofield OMV, Eady RAJ (1994) Epidermolysis bullosa pruriginosa: dystrophic epidermolysis bullosa with distinctive clinicopathological features. Br J Dermatol 130:617–625

    PubMed  CAS  Google Scholar 

  25. Mellerio JE, Ashton GHS, Mohammedi R, Lyon CC, Kirby B, et al (1999) Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol 112:984–987

    PubMed  CAS  Google Scholar 

  26. Mellerio JE, Weiner M, Denyer J, et al (2007) Medical management of epidermolysis bullosa: proceedings of the IInd international symposium on epidermolysis bullosa, Santiago, Chile, 2005. Int J Dermatol 46:795–800

    PubMed  Google Scholar 

  27. Murata T, Masunaga T, Shimizu H, et al (2000) Glycine substitution mutations by different amino acids in the same codon of COL7A1 lead to heterogeneous clinical phenotypes of dominant dystrophic epidermolysis bullosa. Arch Dermatol Res 292:477–481

    PubMed  CAS  Google Scholar 

  28. Nasca MR, O’Toole EA, Palicharla P, et al (1999) Thalidomide increases human keratinocytes migration and proliferation. J Invest Dermatol 113:720–724

    PubMed  CAS  Google Scholar 

  29. Ozanic Bulic S, Fassihi H, Mellerio J, McGrath JA, Atherton DJ (2005) Thalidomide in the management of epidermolysis bullosa pruriginosa. Br J Dermatol 152:1332–1334

    PubMed  CAS  Google Scholar 

  30. Schmelz M (2002) Itch: mediators and mechanisms. J Dermatol Sci 28:91–96

    PubMed  CAS  Google Scholar 

  31. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO (2003) Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 89:2441–2448

    PubMed  CAS  Google Scholar 

  32. Schnyder UW, Elchhoff D (1964) Zur Klinik und Genetik der dominant-dystrophischen epidermolysis bullosa hereditaria. Arch Klin Exp Derm 218:62–90

    Google Scholar 

  33. Sperber J, Shaw J, Bruce S (1989) Psychological components and the role of adjunct interventions in chronic idiopathic urticaria. Psychother Psychosom 51:135–141

    PubMed  CAS  Google Scholar 

  34. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T (2003) Neurophysiology of pruritus — cutaneous elicitation of itch. Arch Dermatol 139:1463–1470

    PubMed  Google Scholar 

  35. Twycross R, Greaves MW, Handwerker H, et al (2003) Itch: scratching more than the surface. QJM 96:7–26

    PubMed  CAS  Google Scholar 

  36. Wang Y, Zhao J, Tu P, Jiang W, Zhu X (2007) A novel missense mutation in COL7A1 in a Chinese pedigree with epidermolysis bullosa pruriginosa. J Dermatol Sci 46:211–213

    PubMed  CAS  Google Scholar 

  37. Wei ET, Seid DA (1983) AG-3-5: a chemical producing sensations of cold. J Pharm Pharmacol 35:110–112

    PubMed  CAS  Google Scholar 

  38. Weisshaar E, Kucenic MJ, Fleischer ABJ (2003) Pruritus: a review. Acta Derm Venereol [Suppl] 213:5–32

    Google Scholar 

  39. Willebrand M, Low A, Dyster-Aas J, et al (2004) Pruritus, personality traits and coping in long-term follow-up of burn-injured patients. Acta Derm Venereol 84:385–390

    Google Scholar 

  40. Yamasaki H, Tada J, Yoshioka T, et al (1997) Epidermolysis bullosa pruriginosa (McGrath) successfully controlled by oral cyclosporin. Br J Dermatol 137:308–310

    PubMed  CAS  Google Scholar 

  41. Yosipovitch G, Greaves MW, Schmelz M (2003) Itch. Lancet 361:690–694

    PubMed  Google Scholar 

References

  1. Azizkhan R, Stehr W, Cohen AP, et al (2006) Esophageal strictures in children with recessive dystrophic epidermolysis bullosa: an 11-year experience with fluoroscopically guided balloon dilatation. J Pediatr Surg 41:55–60

    PubMed  Google Scholar 

  2. Azizkhan RG, Denyer JE, Mellerio JE, et al (2007) Surgical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol 46:801–808

    PubMed  Google Scholar 

  3. Ciccarelli AO, Rothaus KO, Carter DM, Lin AN (1995) Plastic and reconstructive surgery in epidermolysis bullosa: clinical experience with 110 procedures in 25 patients. Ann Plast Surg 35:254–261

    PubMed  CAS  Google Scholar 

  4. Demirogullari B, Sonmez K, Turkyilmaz Z, et al (2001) Colon interposition for esophageal stenosis in a patient with epidermolysis bullosa. J Pediatr Surg 12:1861–1863

    Google Scholar 

  5. Feurle GE, Weidauer H, Baldauf G, Schulte-Braucks T, Anton-Lamprecht I (1984) Management of esophageal stenosis in recessive dystrophic epidermolysis bullosa. Gastroenterology 87:1376–1380

    PubMed  CAS  Google Scholar 

  6. Fine J-D, Johnson LB, Weiner M, et al (2004) Eye involvement in inherited epidermolysis bullosa (EB): experience of the National EB Registry. Am J Ophthalmol 138:254–262

    PubMed  Google Scholar 

  7. Fine J-D, Johnson LB, Weiner M, et al (2005) Pseudosyndactyly and musculoskeletal deformities in inherited epidermolysis bullosa (EB): experience of the National EB Registry, 1986–2002. J Hand Surg (British and European Volume) 30B:14–22

    Google Scholar 

  8. Glicenstein J, Mariani D, Haddad R (2000) The hand in recessive epidermolysis bullosa. Hand Clinics 16:637–645

    PubMed  CAS  Google Scholar 

  9. Gough MJ, Page RE (1979) Surgical correction of the hand in epidermolysis bullosa dystrophica. Hand 11:55–58

    PubMed  CAS  Google Scholar 

  10. Greider JL Jr, Flatt AE (1983) Care of the hand in recessive epidermolysis bullosa. Plast Reconstr Surg 72:222–227

    PubMed  Google Scholar 

  11. Greider JL Jr, Flatt AE (1988) Surgical restoration of the hand in epidermolysis bullosa. Arch Dermatol 124:765–767

    PubMed  CAS  Google Scholar 

  12. Haynes L, Atherton DJ, Ade-Ajayi N, Wheeler R, Kiely EM (1996) Gastrostomy and growth in dystrophic epidermolysis bullosa. Br J Dermatol 134:872–879

    PubMed  CAS  Google Scholar 

  13. Kljenak A (2003) Zagreb surgical reconstructive procedure (ZSRP) for hands affected by EB. In: Atherton D, Martinez AE, Mellerio JE (eds) Clinical management of children and adults with epidermolysis bullosa. Great Ormond Street Hospital for Children NHS Trust and the Institute of Child Health. DebRA-UK, London, pp 51–52

    Google Scholar 

  14. Marin-Bertolin S, Amaya S, Valero JV, Neira Gimenez C, Marquina Vila P, Amorrortu-Velayos J (1999) Surgical management of hand contractures and pseudosyndactyly in dystrophic epidermolysis bullosa. Ann Plast Surg 43:555–559

    PubMed  CAS  Google Scholar 

  15. Okada T, Sasaki F, Shimizu H, et al (2006) Effective esophageal balloon dilatation for esophageal stenosis due to epidermolysis bullosa. Eur J Pediatr Surg 16:115–119

    PubMed  CAS  Google Scholar 

  16. Rodriguez-Baez N, Andersen JM (2003) Management of esophageal strictures in children. Curr Treat Options Gastroenterol 6:417–425

    PubMed  Google Scholar 

  17. Siepe P, Roessing C, Safi A (2002) Dystrophic epidermolysis bullosa: surgical treatment of advanced hand deformities. Handchir Mikrochir Plast Chir 34:307–313

    PubMed  CAS  Google Scholar 

  18. Smith P, Nizam M, Mullett F (1988) Epidermolysis bullosa. In: Buck-Gramcko D (ed) Congenital malformations of the hand and forearm. Churchill-Livingstone, London

    Google Scholar 

  19. Terrill PJ, Mayou BJ, Pemberton J (1992) Experience in the surgical management of the hand in dystrophic epidermolysis bullosa. Br J Plast Surg 45:432–442

    Google Scholar 

  20. Vozdvishensky SI, Albanova VI (1993) Surgical treatment of contracture and syndactyly of children with epidermolysis bullosa. Br J Plast Surg 46:314–316

    Google Scholar 

References

  1. Department of Health and Social Security Report on Health and Social Subjects No. 32: Present day practice in infant feeding (1988). The Stationery Office, London

    Google Scholar 

  2. Department of Health Report on Health and Social Subjects No. 41: Dietary references values for food energy and nutrients for the United Kingdom (1991). The Stationery Office, London

    Google Scholar 

  3. Allman S, Haynes L, MacKinnon P, Atherton DJ (1992) Nutrition in dystrophic epidermolysis bullosa. Pediatr Dermatol 9:231–238

    PubMed  CAS  Google Scholar 

  4. Atherton DJ, Mellerio JE, Denyer J (2006) Epidermolysis Bullosa. In: Harper J, Oranje A, Prose N (eds) Textbook of paediatric dermatology, 2nd edn. Blackwell Publishing, Oxford

    Google Scholar 

  5. Azevedo VMP, Albanesi Filho FM, Santos MA, Castier MB, Tura BR (2004) The impact of malnutrition on idiopathic dilated cardiomyopathy in children. J Pediatr (Rio J) 80:211–216

    Google Scholar 

  6. Azizkhan R, Stehr W, Cohen AP, et al (2006) Esophageal strictures in children with recessive dystrophic epidermolysis bullosa: an 11-year experience with fluoroscopically guided balloon dilatation. J Pediatr Surg 41:55–60

    PubMed  Google Scholar 

  7. Beard JL (1998) Weekly iron intervention: the case for intermittent iron supplementation. Amer J Clin Nutr 68:209–212

    PubMed  CAS  Google Scholar 

  8. Birge K (1995) Nutrition management of patients with epidermolysis bullosa. J Am Diet Assoc 95:575–579

    PubMed  CAS  Google Scholar 

  9. Chandra RK (1984) Excessive intake of zinc impairs immune responses. JAMA 252:1443–1446

    PubMed  CAS  Google Scholar 

  10. Clayden GS (1990) Dysphagia and constipation in epidermolysis bullosa. In: Priestley GC, Tidman MJ, Weiss JB, Eady RAJ (eds) Epidermolysis bullosa: a comprehensive review of classification, management and laboratory studies, dystrophic epidermolysis bullosa research Association (DebRA). Berkshire

    Google Scholar 

  11. Ergun GA, Lin AN, Dannenberg AJ, Carter DM (1992) Gastrointestinal manifestations of epidermolysis bullosa. A study of 101 patients. Medicine (Baltimore) 71:121–127

    CAS  Google Scholar 

  12. Fewtrell MS, Allgrove J, Gordon I, et al (2006) Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 154:959–962

    PubMed  CAS  Google Scholar 

  13. Field D, Garland M, Williams K (2003) Correlates of specific childhood feeding problems. J Paediatr Child Health 39:299–304

    PubMed  CAS  Google Scholar 

  14. Fine JD, Tamura T, Johnson L (1989) Blood vitamin and trace metal levels in epidermolysis bullosa. Arch Dermatol 125:374–379

    PubMed  CAS  Google Scholar 

  15. Fine JD, McGuire J (1999) Altered nutrition and inherited epidermolysis bullosa. In: Fine JD, Bauer EA, McGuire J, Moshell A (eds) Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances, and the findings of the National Epidermolysis Bullosa Registry. Johns Hopkins University Press, Baltimore

    Google Scholar 

  16. Fox AT, Alderdice F, Atherton DJ (2003) Are children with recessive dystrophic epidermolysis bullosa of low birthweight? Ped Dermatol 20:303–306

    CAS  Google Scholar 

  17. Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA (1995) Cross sectional stature and weight reference curves for the UK. Arch Dis Child 73:17–24

    PubMed  CAS  Google Scholar 

  18. Gamelli RL (1988) Nutritional problems of the acute and chronic burn patient. Relevance to epidermolysis bullosa. Arch Dermatol 124:756–759

    PubMed  CAS  Google Scholar 

  19. Giardina PJ, Lin AN (1992) Hematologic problems in epidermolysis bullosa. In: Lin AN, Carter DM (eds) Epidermolysis bullosa: basic and clinical aspects. Springer, New York

    Google Scholar 

  20. Hallberg L (1998) Combating iron deficiency: daily administration of iron is far superior to weekly administration. Am J Clin Nutr 68:213–217

    PubMed  CAS  Google Scholar 

  21. Haynes L, Atherton DJ, Ade-Ajayi N, Wheeler R, Kiely EM (1996) Gastrostomy and growth in dystrophic epidermolysis bullosa. Br J Dermatol 134:872–879

    PubMed  CAS  Google Scholar 

  22. Haynes L, Atherton DJ, Clayden G (1997) Constipation in epidermolysis bullosa: successful treatment with a liquid-fiber-containing formula. Ped Dermatol 5:393–396

    Google Scholar 

  23. Haynes L (2007) Epidermolysis bullosa. In: Shaw V, Lawson M (eds) Clinical paediatric dietetics, 3rd edn. Blackwell Science, Oxford

    Google Scholar 

  24. Haynes L (2007) Clinical practice guidelines for nutrition support in children with epidermolysis bullosa including THINC (Tool to Help Identify Nutritional Compromise in EB) Great Ormond Street Hospital 2007

    Google Scholar 

  25. Ingen-Housz-Oro S, Blanchet-Bardon C, Vrillat M, Dubertret L (2004) Vitamin and trace levels in recessive dystrophic epidermolysis bullosa. JEADV 18:649–653

    PubMed  CAS  Google Scholar 

  26. Lachaux A, Bouvier R, Loras-Duclaux I, Chappuis JP, Meneguzzi G, Ortonne JP (1999) Isolated deficient alpha6 beta4 integrin expression in the gut associated with intractable diarrhea. J Ped Gastr Nutr 29:395–401

    CAS  Google Scholar 

  27. Lechner-Gruskay D, Honig PJ, Pereira G, McKinney S (1988) Nutritional and metabolic profile of children with epidermolysis bullosa. Pediatr Dermatol 5:22–27

    PubMed  CAS  Google Scholar 

  28. Levene CI, Bates CJ (1975) Ascorbic acid and collagen synthesis in cultured fibroblasts. Ann NY Acad Sci 258:288–305

    PubMed  CAS  Google Scholar 

  29. Malone AM (2000) Supplemental zinc in wound healing: is it beneficial? Nutr Clin Prac 15:253–256

    Google Scholar 

  30. Mathisen B, Worral L, Masel J, Wall C, Shepherd RW (1999) Feeding problems in infants with gastro-oesophageal reflux disease: a controlled study. J Paediatr Child Health 35:163–169

    PubMed  CAS  Google Scholar 

  31. Melville C, Atherton D, Burch M, Cohn A, Sullivan I (1996) Fatal cardiomyopathy in dystrophic epidermolysis bullosa. Br J Dermatol 135:603–606

    PubMed  CAS  Google Scholar 

  32. Orlando RC, Bozymski EM, Briggaman RA, Bream CA (1974) Epidermolysis bullosa: gastrointestinal manifestations. Ann Int Med 81:203–206

    PubMed  CAS  Google Scholar 

  33. Sehgal VN, Rege VL, Ghosh SK, Kamat SM (1977) Dystrophic epidermolysis bullosa. Interesting gastrointestinal manifestations. Br J Dermatol 96:389–391

    PubMed  CAS  Google Scholar 

  34. Seshadri A, Shah A, Bhade S (1985) Haematological response of anaemic preschool children to ascorbic acid supplementation. Hum Nutr Appl Nutr 39A:151–154

    Google Scholar 

  35. Shah N, Freeman E, Martinez A, Mellerio J, Smith VV, Sebire NJ (2007) Histopathological features of gastrointestinal mucosal biopsy specimens in children with epidermolysis bullosa. J Clin Pathol 60:843–844

    PubMed  CAS  Google Scholar 

  36. Shankar AH, Prasad AS (1998) Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr 68 [Suppl]:447S–463S

    PubMed  CAS  Google Scholar 

  37. Shenkin A (2006) The key role of micronutrients. Clin Nutr 25:1–13

    PubMed  CAS  Google Scholar 

  38. Sidwell RU, Yates R, Atherton D (2000) Dilated cardiomyopathy in dystrophic epidermolysis bullosa. Arch Dis Child 83:59–63

    PubMed  CAS  Google Scholar 

  39. Smith PK, Davidson GP, Moore L, et al (1993) Epidermolysis bullosa and severe ulcerative colitis in an infant. J Pediatr 122:600–603

    PubMed  CAS  Google Scholar 

  40. Soriano LF, Lage Vazquez MA, Perez-Portabella Maristany C, Xandri Graupera JM, Wouters-Wessling W, Wagenaar L (2004) The effectiveness of oral nutritional supplementation in the healing of pressure ulcers. J Wound Care 13:319–322

    Google Scholar 

  41. Stewart L, McKaig N, Dunlop C, Daly H, Almond S (2006) Dietetic assessment and monitoring of children with special needs with faltering growth. British Dietetic Association Paediatric Group Professional Consensus Statement

    Google Scholar 

  42. Taibjee SM, Ramani P, Brown R, Moss C (2005) Lethal cardiomyopathy in epidermolysis bullosa associated with amitryptiline. Arch Dis Child 90:871–872

    PubMed  CAS  Google Scholar 

  43. Tesi D, Lin AN (1992) Nutritional management of the epidermolysis bullosa patient. In: Lin AN, Carter DM (eds) Epidermolysis bullosa: basic and clinical aspects. Springer, New York

    Google Scholar 

  44. Thompson C, Furhman MP (2005) Nutrients and wound healing: still searching for the magic bullet. Nutr Clin Prac 20:331–347

    Google Scholar 

  45. Van den Berghe G (2002) Dynamic neurodendocrine responses to critical illness. Front Neuroendocrinol 23:370–391

    PubMed  Google Scholar 

  46. Walker CF, Kordas K, Stolzfus RJ, Black RE (2005) Interactive effects of iron and zinc on biochemical and functional outcomes in supplementation trials. Am J Clin Nutr 82:5–12

    CAS  Google Scholar 

  47. Walpir RA (1998) Copper absorption and bioavailability. Am J Clin Nutr 67 [Suppl]:1054S–1060S

    Google Scholar 

  48. Whittaker P (1998) Iron and zinc interactions in humans. Am J Clin Nutr 68 [Suppl]:442S–446S

    PubMed  CAS  Google Scholar 

  49. Williams CL, Bollella M, Wynder EL (1995) A new recommendation for dietary fiber in childhood. Pediatr 96:985–988

    CAS  Google Scholar 

  50. Yan EG, Paris JJ, Ahluwalia J, Lane AT, Bruckner AL (2007) State-of-the-art. Treatment decision-making for patients with the Herlitz subtype of junctional epidermolysis bullosa. J Perinatol 27:307–311

    PubMed  CAS  Google Scholar 

References

  1. Burger-Rafael M (2005) Bewegungstherapie bei Schmetterlingskindern, Physikalische Medizin und Rehabilitation, 11–12

    Google Scholar 

  2. EB Info world 2007

    Google Scholar 

  3. Frostig M (1999) Educational therapy (Bewegungserziehung). Reinhardt, München

    Google Scholar 

  4. Herber OR (2005) Klinische und psychosoziale Aspekte bei Epidermolysis bullosa. Verlag Zimmermann, Dorsten

    Google Scholar 

  5. Ieran M, Zaffut OS (1990) Effect of low frequency pulsing electromagnetic fields on skin ulcers of venous origin in humans. J Orthop Res 8:276–282

    PubMed  CAS  Google Scholar 

  6. Kam TI (1988) Molecular mechanism of the therapeutic effect of low intensity laser irradiation. Lasers Life Sci 2:53–74

    Google Scholar 

  7. Ladd AL, et al (1996) Surgical treatment and postoperative splinting of recessive dystrophic epidermolysis bullosa. J Hand Surg 5:888–897

    Google Scholar 

  8. Ledev VV (1991) Possible mechanism for influence of weak magnetic fields on biological systems. Bioelectromagnetics (N.Y.) 12:71–75

    Google Scholar 

  9. Pölzleitner M-C (2007) Unveröffentlichte Diplomarbeit, 74–93

    Google Scholar 

References

  1. Aiuti A, Cassani B, Andolfi G, et al (2007) Multilineage hematopoietic reconstitution without cloncal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117:2233–2240

    PubMed  CAS  Google Scholar 

  2. Andreadis ST (2004) Gene transfer to epidermal stem cells: implications for tissue engineering. Expert Opin Biol Ther 4:783–800

    PubMed  CAS  Google Scholar 

  3. Arakawa M, Shiozuka M, Nakayama Y, et al (2003) Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem (Toyko) 134:751–758

    CAS  Google Scholar 

  4. Bajaj BG, Lei P, Andreadis ST (2005) Efficient gene transfer to human epidermal keratinocytes on fibronectin: in vitro evidence for transduction of epidermal stem cells. Mol Therapy 11:969–979

    CAS  Google Scholar 

  5. Baldeschi C, Gache Y, Rattenholl A, et al (2003) Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet 12:1897–1905

    PubMed  CAS  Google Scholar 

  6. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375–381

    PubMed  CAS  Google Scholar 

  7. Bodemer C, Tchen SI, Ghomrasseni S, et al (2003) Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation. J Invest Dermatol 121:273–279

    PubMed  CAS  Google Scholar 

  8. Bushman FD (2007) Retroviral integration and human gene therapy. J Clin Invest 117:2083–2086

    PubMed  CAS  Google Scholar 

  9. Cao T, Longley MA, Wang XJ, Roop DR (2001) An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J Cell Biol 152:651–656

    PubMed  CAS  Google Scholar 

  10. Cavazzana-Calvo M, Hacein-Bey-Abina S, De Saint Basile G, et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672

    PubMed  CAS  Google Scholar 

  11. Cavazzana-Calvo M, Trasher A, Mavilio F (2004) The future of gene therapy. Nature 427:779–781

    PubMed  CAS  Google Scholar 

  12. Chao H, Mansfield SG, Bartel RC, et al (2003) Phenotype correction of hemophilia A mice by spliceosome mediated RNA trans-splicing. Nat Med 9:1015–1019

    PubMed  CAS  Google Scholar 

  13. Chen M, O’Toole EA, Muellenhoff M, et al (2000) Development and characterization of a recombinant truncated type VII collagen “minigene”. J Biol Chem 275:24429–24435

    PubMed  CAS  Google Scholar 

  14. Chen M, Kasahara N, Keene DR, et al (2002) Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32:670–675

    PubMed  CAS  Google Scholar 

  15. Christiano AM, Pulkkinen L, Eady RA, Uitto J (1996) Compound heterozygosity for nonsense and missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa. J Invest Dermatol 106:775–777

    PubMed  CAS  Google Scholar 

  16. D’Alessandro M, Morley SM, Ogden PH, Liovic M, Porter RM, Lane EB (2004) Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases. Gene Ther 11:1290–1295

    PubMed  CAS  Google Scholar 

  17. Dallinger G, Puttaraju M, Mitchell LG, et al (2003) Development of spliceosomemediated RNA trans-splicing (SMaRT trade mark) for the correction of inherited skin diseases. Exp Dermatol 12:37–46

    PubMed  CAS  Google Scholar 

  18. Darling TN, Yee C, Bauer JW, Hintner H, Yancey KB (1999) Revertant mosaicism: partial correction of a germline mutation in COL17A1 by a frame-resorting mutation. J Clin Invest 103:1371–1377

    PubMed  CAS  Google Scholar 

  19. Dellambra E, Vailly J, Pellegrini G, et al (1998) Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum Gene Ther 9:1359–1370

    PubMed  CAS  Google Scholar 

  20. Dellambra E, Prislei S, Salvati A, et al (2001) Gene correction of integrin beta4dependent pyloric atresia-junctional epidermolysis bullosa KCs establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly. J Biol Chem 276:41336–41342

    PubMed  CAS  Google Scholar 

  21. Dunnwald M, Tomanek-Chalkley A, Alexandrunas D, Fishbaugh J, Bickenbach JR (2001) Isolating a pure population of epidermal stem cells for use in tissue engineering. Exp Dermatol 10:45–54

    PubMed  CAS  Google Scholar 

  22. Featherstone C (2007) Epidermolysis bullosa: from fundamental molecular biology to clinical therapies. J Invest Dermatol 127:256–259

    PubMed  CAS  Google Scholar 

  23. Ferrari S, Pellegrini G, Matsui T, Mavilio F, De Luca M (2006) Gene therapy in combination with tissue engineering to treat epidermolysis bullosa. Exp Opin Biol Ther 6:367–378

    CAS  Google Scholar 

  24. Gache Y, Baldeschi C, Del Rio M, et al (2004) Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 15:921–933

    PubMed  CAS  Google Scholar 

  25. Gaspar HB, Thrasher AJ (2005) Gene therapy for severe combined immunodeficiencies. Exp Opin Biol Ther 5:1175–1182

    CAS  Google Scholar 

  26. Georges-Labouesse E, Messaddeq N, Yehia G, Cadalbert L, Dierich A, LeMeur M (1996) Absence of integrin α6 leads to epidermolysis bullosa and neonatal death in mice. Nature Genet 13:370–373

    PubMed  CAS  Google Scholar 

  27. Goto M, Sawamura D, Ito K, et al (2006) Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol 126:766–772

    PubMed  CAS  Google Scholar 

  28. Guerra L, et al (2000) Treatment of “stable” vitiligo by Timedsurgery and transplantation of cultured epidermal autografts. Arch Dermatol 136:1380–1389

    PubMed  CAS  Google Scholar 

  29. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419

    PubMed  CAS  Google Scholar 

  30. Heinonen S, Manniko M, Klement JF, Whitaker-Menezes D, Murphy GF, Uitto J (1999) Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci 112:3614–3648

    Google Scholar 

  31. Hickerson RP, Smith FJ, Reeves RE, et al (2008) Single-nucleotide-specifics iRNA targeting in a dominant negative skin model. J Invest Dermatol 128:594–605

    PubMed  CAS  Google Scholar 

  32. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 97:9618–9623

    PubMed  CAS  Google Scholar 

  33. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF (2000) Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48:164–169

    PubMed  CAS  Google Scholar 

  34. Irvine AD, McLean WHI (1999) Human keratin diseases: The increasing spectrum of disease and subtlety of the phenotype-genotype correlation. Br J Dermatol 140:815–828

    PubMed  CAS  Google Scholar 

  35. Jensen TG, Sorensen CB, Jensen UB, Bolund L (2003) Epidermolysis bullosa simplex KCs with extended lifespan established by ectopic expression of telomerase. Exp Dermatol 12:71–77

    PubMed  CAS  Google Scholar 

  36. Jiang Q-L, Uitto J (2005) Animal models of epidermolysis bullosa — targets for gene therapy. J Invest Dermatol 124:xi–xiii

    PubMed  CAS  Google Scholar 

  37. Jonkman MF, Scheffer H, Stulp R, et al (1997) Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 88:543–551

    PubMed  CAS  Google Scholar 

  38. Khavari PA, Rollman O, Vahlquist A (2002) Cutaneous gene transfer for skin and systemic diseases. J Internal Med 252:1–10

    PubMed  CAS  Google Scholar 

  39. Kirfel J, Peters B, Grund C, Reifenberg K, Magin TM (2002) Ectopic expression of desmin in the epidermis of transgenic mice permits development of a normal epidermis. Differentiation 70:56–68

    PubMed  CAS  Google Scholar 

  40. Kolodka TM, Garlick JA, Taichman LB (1998) Evidence for KC stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced KCs. Proc Natl Acad Sci USA 95:4356–4361

    PubMed  CAS  Google Scholar 

  41. Lacerra G, Sierakowska H, Carestia C, et al (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 97:9591–9596

    PubMed  CAS  Google Scholar 

  42. Laimer M, Lanschuetzer C, Hintner H, Bauer JW (2006) Current approaches to cutaneous gene therapy. Exp Rev Dermatol 1:833–853

    CAS  Google Scholar 

  43. Lan N, Howrey RP, Lee SW, Smith CA, Sullenger BA (1998) Ribozyme-mediated repair of sickle betaglobin mRNAs in erythrocyte precursors. Science 280:1593–1596

    PubMed  CAS  Google Scholar 

  44. Li A, Pouliot N, Redvers R, Kaur P (2004) Extensive tissue-regenerative capacity of neonatal human keratinocyte stem cells and their progeny. J Clin Invest 113:390–400

    PubMed  CAS  Google Scholar 

  45. Liu X, Jiang Q, Mansfield SG, et al (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA transsplicing. Nat Biotechnol 20:47–52

    PubMed  CAS  Google Scholar 

  46. Lloyd C, Yu Q-C, Cheng J, et al (1995) The basal keratin network of stratified squamous epithelia: defining K15 function in the absence of K14. J Cell Biol 129:1329–1344

    PubMed  CAS  Google Scholar 

  47. Lowenstein PR (2003) Virology and immunology of gene therapy, or virology and immunology of high MOI infection with defective viruses. Gene Ther 10:933–998

    PubMed  CAS  Google Scholar 

  48. Magin TM, Kaiser HW, Leitgeb S, et al (2000) Supplementation of a mutant keratin by stable expression of desmin in cultured human EBS KCs. J Cell Sci 113:4231–4239

    PubMed  CAS  Google Scholar 

  49. Mavilio F, Pellegrini G, Ferrari S, et al (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12:1397–1402

    PubMed  CAS  Google Scholar 

  50. McGrath JA, Gatalica B, Christiano AM, et al (1995) Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 11:83–86

    PubMed  CAS  Google Scholar 

  51. McGrath JA, Ashton GH, Mellerio JE, et al (1999) Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing nonsense or frameshift mutations. J Invest Dermatol 113:314–321

    PubMed  CAS  Google Scholar 

  52. McLean I, Terron A (2002) Ribozyme gene therapy strategies for keratin disorders. J Invest Dermatol 119:268

    Google Scholar 

  53. Mecklenbeck S, Compton SH, Mejia JE, et al (2002) A microinjected COL7A1-PAC vector restores synthesis of intact procollagen VII in a dystrophic epidermolysis bullosa KC cell line. Hum Gene Ther 13:1655–1662

    PubMed  CAS  Google Scholar 

  54. Meng X, Klement JF, Leperi DA, et al (2003) Targeted inactivation of murine gamma2-chain gene recapitulates human junctional epidermolysis bullosa. J Invest Dermatol 121:720–731

    PubMed  CAS  Google Scholar 

  55. Morris RJ, Liu Y, Maries L, et al (2004) Capturing and profiling adult hair follicle stem cells. Nat Biotechnol 22:411–417

    PubMed  CAS  Google Scholar 

  56. Ortiz-Urda S, Thyagarajan B, Keene DR, et al (2002) Stable nonviral genetic correction of inherited human skin disease. Nat Med 8:1166–1170

    PubMed  CAS  Google Scholar 

  57. Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA (2003) Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 111:251–255

    PubMed  CAS  Google Scholar 

  58. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA (2003) Sustainable correction of junctional epidermolysis bullosa via transposonmediated nonviral gene transfer. Gene Ther 10:1099–1104

    PubMed  CAS  Google Scholar 

  59. Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA (2003) PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther 14:923–928

    PubMed  CAS  Google Scholar 

  60. Palazzi X, Marchai T, Chabanne L, Spadafora A, Magnol JP, Meneguzzi G (2000) Inherited dystrophic epidermolysis bullosa in inbred dogs: a spontaneous animal model for somatic gene therapy. J Invest Dermatol 115:135–137

    PubMed  CAS  Google Scholar 

  61. Pasmooij AMG, Pas HH, Deviaene FCL, Nijenhuis M, Jonkman MF (2005) Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum Genet 77:727–740

    PubMed  CAS  Google Scholar 

  62. Pasmooij AMG, Pas HH, Boiling MC, Jonkman MF (2007) Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest 117:1240–1248

    PubMed  CAS  Google Scholar 

  63. Peters B, Kirfel J, Buessow H, Vidal M, Magin TM (2001) Complete cytolysis and neonatal lethality in keratin 5 knockout mice reveal its fundamental role in skin integrity and in epidermolysis bullosa simplex. Mol Biol Cell 12:1775–1786

    PubMed  CAS  Google Scholar 

  64. Pohla-Gubo G, et al (1995) Diminished expression of the extracellular domain of bullous pemphigoid antigen 2 (BPAG2) in the epidermal basement of patients with generalized atrophic benign epidermolysis bullosa. Exp Dermatol 4:199–206

    PubMed  CAS  Google Scholar 

  65. Politano L, Nigro G, Nigro V, et al (2003) Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 22:15–21

    PubMed  CAS  Google Scholar 

  66. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG (1999) Spliceosome-mediated RNA trans-splicing as a tool for gene therapy. Nat Biotechnol 17:246–252

    PubMed  CAS  Google Scholar 

  67. Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA (2001) In vivo restoration of laminin 5 beta expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci USA 98:5193–5198

    PubMed  CAS  Google Scholar 

  68. Robbins PB, Sheu SM, Goodnough JB, Khavari PA (2001) Impact of laminin 5 beta 3 gene versus protein replacement on gene expression patterns in junctional epidermolysis bullosa. Hum Gene Ther 12:1443–1448

    PubMed  CAS  Google Scholar 

  69. Ruzzi L, Pas H, Posteraro P, et al (2001) A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol 116:182–187

    PubMed  CAS  Google Scholar 

  70. Ryan MC, Keesook L, Miyashita Y, Carter WC (1999) Targeted disruption of the LAMA3 gene in mice reveals abnormalities in survival and late stage differentiation of epithelial cells. J Cell Biol 145:1309–1323

    PubMed  CAS  Google Scholar 

  71. Sat E, Leung KH, Bruckner-Tuderman L, Cheah KS (2000) Tissue-specific expression and long-term deposition of human collagen VII in the skin of transgenic mice: implications for gene therapy. Gene Ther 7:1631–1639

    PubMed  CAS  Google Scholar 

  72. Schuilenga-Hut PHL, Scheffer H, Pas HH, Nijenhuis M, Buys CHCM, Jonkman MF (2002) Partial revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex. J Invest Dermatol 118:626–630

    PubMed  CAS  Google Scholar 

  73. Seitz CS, Giudice GJ, Balding SD, Marinkovich MP, Khavari PA (1999) BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther 6:42–47

    PubMed  CAS  Google Scholar 

  74. Singh A, Ursic D, Davies J (1979) Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature 277:146–148

    PubMed  CAS  Google Scholar 

  75. Smith FJD, Morley SM, McLean WHI (2004) Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. J Invest Dermatol 122:73–77

    PubMed  CAS  Google Scholar 

  76. Spirito F, Charlesworth A, Linder K, Ortonne JP, Baird J, Meneguzzi G (2002) Animal models for skin blistering conditions: absence of laminin 5 causes hereditary junctional mechanobullous disease in the Belgian horse. J Invest Dermatol 119:684–691

    PubMed  CAS  Google Scholar 

  77. Tumbar T, Guasch G, Greco V, et al (2004) Defining the epithelial stem cell niche in skin. Science 303:359–363

    PubMed  CAS  Google Scholar 

  78. Uitto J, Pulkkinen L(2001) Molecular genetics of heritable blistering disorders. Arch Dermatol 137:1458–1461

    PubMed  CAS  Google Scholar 

  79. Vailly J, Gagnoux-Palacios L, Dell’ambra E, et al (1998) Corrective gene transfer of KCs from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther 5:1322–1332

    PubMed  CAS  Google Scholar 

  80. van der Neut R, Krimpenfort P, Calafat J, Niessen CM, Sonnenberg A (1996) Epithelial detachment due to absence of hemidesmosomes in integrin β4 null mice. Nature Genet 13:366–369

    PubMed  Google Scholar 

  81. Van den Driessche T, Collen D, Chuah MK (2003) Gene therapy for the hemophilias. J Thromb Haemost 1:1550–1558

    Google Scholar 

  82. Vogel J (2003) The virtue of tolerance. J Invest Dermatol 120:610–615

    Google Scholar 

  83. Wagner KR, Hamed S, Hadley DW, et al (2001) Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49:706–711

    PubMed  CAS  Google Scholar 

  84. Wally V, Klausegger A, Koller U, et al (2008) 5′ trans-splicing repair of the PLEC1 gene. J Invest Dermatol 128:568–574

    PubMed  CAS  Google Scholar 

  85. Wilschanski M, Yahav Y, Yaacov Y, et al (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349:1433–1441

    PubMed  CAS  Google Scholar 

  86. Woodley DT, Rrueger GG, Jorgensen CM, et al (2003) Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121:1021–1028

    PubMed  CAS  Google Scholar 

  87. Woodley DT, Keen DR, Atha T, et al (2004) Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10:318–326

    PubMed  CAS  Google Scholar 

  88. Woodley DT, Keen DR, Atha T, et al (2004) Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat Med 10:693–695

    PubMed  CAS  Google Scholar 

  89. Woodley DT, Remington J, Huang Y, et al (2007) Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther 15:628–635

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Dermatologie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Austria

    Dr. Christoph M. Lanschuetzer, Dr. Elke Nischler, Dr. Anja Diem, Dr Gabriela Pohla-Gubo, Prof. Dr. Helmut Hintner, Dr. Martin Laimer & Univ.-Doz. Dr. Johann W. Bauer

  2. debra-austria, Vienna, Austria

    Dr Rainer Riedl (Chairman)

  3. Universitätsklinik für Kinderchirurgie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Austria

    Univ.-Doz. Dr. Barbara Ludwikowski

  4. Paediatric Dietitian for Epidermolysis Bullosa, Great Ormond Street Hospital for Children, London, UK

    Lesley Haynes (RD)

  5. Universitätsklinik für Physikalische Medizin und Rehabilitation, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Austria

    Dr. Margret Burger-Rafael

Authors
  1. Dr. Christoph M. Lanschuetzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Elke Nischler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. Anja Diem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr Gabriela Pohla-Gubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. Helmut Hintner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dr Rainer Riedl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Univ.-Doz. Dr. Barbara Ludwikowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lesley Haynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dr. Margret Burger-Rafael
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dr. Martin Laimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Univ.-Doz. Dr. Johann W. Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Dermatology, Department of Medicine, Vanderbilt University School of Medicine, and National EB Registry, Nashville, Tennessee, USA

    Jo-David Fine

  2. Universitätsklinik für Dermatologie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich

    Helmut Hintner

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this chapter

Cite this chapter

Lanschuetzer, C.M. et al. (2009). Therapeutical Approaches. In: Fine, JD., Hintner, H. (eds) Life with Epidermolysis Bullosa (EB). Springer, Vienna. https://doi.org/10.1007/978-3-211-79271-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-79271-1_3

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-79270-4

  • Online ISBN: 978-3-211-79271-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation